Neurogene Inc. Prepaid Expense and Other Assets, Current
Neurogene Inc. (NGNE) had Prepaid Expense and Other Assets, Current of $3.52 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-11
- 2026-06-30: Prepaid Expense and Other Assets, Current $3.52M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $3.56M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $2.76M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $5.11M.
| Period end | Prepaid Expense and Other Assets, Current |
|---|---|
| 2026-06-30 | $3.52M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $3.56M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $2.76M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $5.11M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $4.47M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $3.80M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $3.52M 10-K · filed 2026-03-24 |
| 2024-09-30 | $4.65M 10-Q · filed 2024-11-18 |
| 2024-06-30 | $5.24M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $4.61M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $3.19M 10-K · filed 2025-03-24 |
| 2022-12-31 | $2.70M 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |